Why we invested in Punto Health
Revolutionizing dementia care with AI
At Abac Nest Ventures, we back founders tackling complex healthcare challenges with technology. When we met Anna Muñoz Farré and Jack Eckersley, founders of Punto Health, we saw a unique opportunity to reshape dementia care through AI.
Dementia affects over 30 million people across Europe and North America, representing not just a healthcare crisis but a trillion-dollar market in urgent need of innovation. With 70% of mild cognitive impairment cases progressing to Alzheimer’s, early detection and continuous management are critical to improving patient outcomes.
Punto Health is changing that. By combining AI-driven digital biomarkers with continuous, real-time care, they are redefining how dementia is detected, managed, and treated. Their approach doesn’t just assist patients and caregivers—it also helps healthcare providers deliver more efficient, proactive, and personalized care.
The role of AI in the future of healthcare
AI-driven solutions are reshaping how we diagnose, monitor, and manage diseases. According to Bessemer Venture Partners’ latest Healthcare AI report, AI is no longer just about providing clinical insights—it is enabling continuous, proactive care. This shift aligns with Punto Health’s mission to evolve dementia care from reactive interventions to real-time, personalized management.
The AI healthcare market reflects this momentum. Investments in AI healthcare reached $19.54 billion in 2023 and are expected to grow to $27.69 billion in 2024, with projections hitting $490.96 billion by 2032. The rapid adoption of AI-driven diagnostics, remote monitoring, and digital biomarkers is a major driver behind this exponential growth.
One of Bessemer’s key findings is that the most successful AI healthcare companies augment human expertise rather than replace it. This is precisely what Punto Health is doing—empowering caregivers and healthcare providers with AI-powered early detection, remote monitoring, and continuous patient support.
The problem: A massive, unmet need in dementia care
Dementia places an enormous emotional and financial burden on patients, families, and healthcare systems. Yet, most solutions today fall short, offering limited early detection tools and fragmented ongoing support.
With an ageing population and rising healthcare costs, the demand for scalable, cost-effective dementia solutions is growing. Traditional healthcare models lack the resources for continuous, personalized monitoring, leading to delayed diagnoses, inefficient care, and increased strain on families and providers.
This is where AI has the potential to change the paradigm—enabling early, accurate diagnosis and ongoing, adaptive care.
Punto Health’s AI-powered solution and cognitive biomarkers
Punto Health has developed a comprehensive AI-driven platform that supports dementia patients at every stage of their journey:
PuntoCare – A mobile app for patients and caregivers featuring an AI-powered assistant that provides 24/7 support, cognitive exercises, and symptom monitoring—helping families manage dementia more effectively and enhancing patient independence.
PuntoClinic – A web platform for healthcare providers that consolidates patient data, enables remote monitoring, and improves care coordination. It also supports pre-screening and patient selection for clinical trials, helping clinicians deliver more efficient and personalized care.
By integrating digital biomarkers based on spontaneous speech analysis, Punto Health is pioneering new, non-invasive ways to detect and monitor cognitive decline. This approach aligns with a larger healthcare trend: moving from reactive, episodic care to continuous, proactive management.
Meet the minds driving Punto Health’s mission
Behind Punto Health is a team with world-class expertise in AI, biomedical engineering, and scalable healthcare technology:
Anna Muñoz Farré (CEO) – An AI scientist and biomedical engineer, with research experience at MIT and UPC-Barcelona Tech and a background in AI healthcare startups (Elvie, BenevolentAI). She has published in top AI and medical journals (NeurIPS, ICML) and was named Upcoming Woman in STEM 2022 by the Catalan Government.
Jack Eckersley (CTO) – A senior software engineer with a background in Physics and Natural Sciences from the University of Cambridge, with prior experience at Morgan Stanley, Thought Machine, and BenevolentAI. His expertise lies in building scalable AI-driven systems, making him the perfect counterpart to Anna’s medical AI expertise.
For more about Anna and Jack’s vision for dementia care, check out their interviews on Science Entrepreneur and Startup Health.
Why we invested: AI-driven future of dementia care
Our investment in Punto Health is rooted in three key beliefs:
Dementia care is a massive unmet need – The current healthcare system is not equipped to handle the growing number of dementia cases, and solutions that enable early detection and personalized management will play a critical role in improving outcomes.
AI is making continuous, personalized care possible – By leveraging AI-driven biomarkers and conversational AI, Punto Health is building an accessible, scalable, and effective solution for dementia management. This aligns with a broader industry movement toward AI-first, patient-centric healthcare.
Punto Health has the right team and clinical partnerships – Their collaboration with ACE Alzheimer Center Barcelona provides them with strong clinical validation and access to a significant patient base, accelerating their ability to prove real-world impact.
As AI healthcare solutions gain traction, we believe Punto Health is positioned at the forefront of an emerging paradigm shift in dementia care.
What’s Next
Our partnership with Punto Health is more than just an investment; it’s a commitment to advancing meaningful innovation in healthcare. Punto Health’s recent selection for the AD Moonshot program underscores its leadership in dementia care and its potential to reshape how neurodegenerative diseases are managed.
Expansion and Next Steps
Punto Health has made significant progress in its clinical rollout, with active pilots in Spain and the United Kingdom, strengthening its presence in key markets. Additionally, the company has established strategic clinical partnerships with ACE Alzheimer Center in Barcelona and the NHS in the UK, reinforcing its validation within top-tier healthcare environments.
With these foundations in place, Punto Health plans to go to market in the second half of 2025 (H2 2025) with PuntoCare, bringing continuous personalised support and care plans to patients, carers and professionals at scale.
With a scalable model, strong partnerships, and a bold vision, Punto Health is well-positioned to lead the way in dementia care. We’re excited to support Anna, Jack, and their team as they bring life-changing technology to the millions affected by dementia.
Stay tuned as we continue to back bold entrepreneurs who are building the future of AI-powered healthcare.
🚀🚀